Bukwang Pharmaceutical Co., Ltd. 003000.KS Stock
Bukwang Pharmaceutical Co., Ltd. Price Chart
Bukwang Pharmaceutical Co., Ltd. 003000.KS Financial and Trading Overview
Bukwang Pharmaceutical Co., Ltd. stock price | 5950 KRW |
Previous Close | 7200 KRW |
Open | 7160 KRW |
Bid | 7250 KRW x 0 |
Ask | 7260 KRW x 0 |
Day's Range | 7160 - 7290 KRW |
52 Week Range | 6800 - 10800 KRW |
Volume | 109.67K KRW |
Avg. Volume | 112.71K KRW |
Market Cap | 496.98B KRW |
Beta (5Y Monthly) | -0.060286 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 KRW |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | December 29, 2021 |
1y Target Est | N/A |
003000.KS Valuation Measures
Enterprise Value | 389.65B KRW |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.5988655 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.038 |
Enterprise Value/EBITDA | 182.215 |
Trading Information
Bukwang Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | -0.060286 |
52-Week Change | -16.57% |
S&P500 52-Week Change | 20.43% |
52 Week High | 10800 KRW |
52 Week Low | 6800 KRW |
50-Day Moving Average | 7945 KRW |
200-Day Moving Average | 8236.35 KRW |
003000.KS Share Statistics
Avg. Volume (3 month) | 112.71K KRW |
Avg. Daily Volume (10-Days) | 117.85K KRW |
Shares Outstanding | 68.45M |
Float | 40.54M |
Short Ratio | N/A |
% Held by Insiders | 30.24% |
% Held by Institutions | 8.08% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | N/A |
Trailing Annual Dividend Yield | N/A |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1.1:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -2.75% |
Operating Margin (ttm) | -1.53% |
Gross Margin | 42.00% |
EBITDA Margin | 1.11% |
Management Effectiveness
Return on Assets (ttm) | -0.47% |
Return on Equity (ttm) | -2.70% |
Income Statement
Revenue (ttm) | 191.23B KRW |
Revenue Per Share (ttm) | 2746.15 KRW |
Quarterly Revenue Growth (yoy) | 0.89% |
Gross Profit (ttm) | N/A |
EBITDA | 2.14B KRW |
Net Income Avi to Common (ttm) | -5259222528 KRW |
Diluted EPS (ttm) | N/A |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 69.8B KRW |
Total Cash Per Share (mrq) | 1181.1 KRW |
Total Debt (mrq) | 988.53M KRW |
Total Debt/Equity (mrq) | 0.37 KRW |
Current Ratio (mrq) | 6.243 |
Book Value Per Share (mrq) | N/A |
Cash Flow Statement
Operating Cash Flow (ttm) | -16311250944 KRW |
Levered Free Cash Flow (ttm) | -5113888256 KRW |
Profile of Bukwang Pharmaceutical Co., Ltd.
Country | South Korea |
State | N/A |
City | Seoul |
Address | 7, Sangdo-ro |
ZIP | 06955 |
Phone | 82 2 828 8114 |
Website | https://www.bukwang.co.kr |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Q&A For Bukwang Pharmaceutical Co., Ltd. Stock
What is a current 003000.KS stock price?
Bukwang Pharmaceutical Co., Ltd. 003000.KS stock price today per share is 5950 KRW.
How to purchase Bukwang Pharmaceutical Co., Ltd. stock?
You can buy 003000.KS shares on the KSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bukwang Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Bukwang Pharmaceutical Co., Ltd. is 003000.KS.
Which industry does the Bukwang Pharmaceutical Co., Ltd. company belong to?
The Bukwang Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Bukwang Pharmaceutical Co., Ltd. have in circulation?
The max supply of Bukwang Pharmaceutical Co., Ltd. shares is 68.45M.
What is Bukwang Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Bukwang Pharmaceutical Co., Ltd. PE Ratio is now.
What was Bukwang Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Bukwang Pharmaceutical Co., Ltd. EPS is 0 KRW over the trailing 12 months.
Which sector does the Bukwang Pharmaceutical Co., Ltd. company belong to?
The Bukwang Pharmaceutical Co., Ltd. sector is Healthcare.